Tailored to fit: New approaches in transplant-ineligible NDMM

Advancements in minimal residual disease detection in myeloma

Novel biomarkers in myeloma: CTCs and cfDNA

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Use of bispecifics and CAR T cells in South America

Revolutionising myeloma treatment through immune profiling

Guiding transplant decisions in multiple myeloma with MRD

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

The case for global gender-neutral HPV vaccination

Cooperative training for medical staff in Côte d'Ivoire: The national radiotherapy and medical oncology center project

Laser oncosurgery - A new perspective in treating cancer